Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor

Keyphrases

• Breast Cancer Cell Lines 100%
• Human Epidermal Growth Factor Receptor 2 (HER2) 100%
• Epidermal Growth Factor Receptor 100%
• Synergistic Inhibition 100%
• Bcl-2 Inhibitor 100%
• Dual Inhibitor 100%
• Lapatinib 66%
• B-cell Lymphoma 2 (Bcl-2) 33%
• MCF-7 33%
• MCF-7 Cells 33%
• Human Tumors 33%
• HA14-1 33%
• Receptor Tyrosine Kinase 33%
• Human Breast Cancer Cell Lines 33%
• ErbB 33%
• GX15-070 33%
• Clinical Trials 16%
• Advanced Cancer Patients 16%
• Covalent Inhibitor 16%
• Human Breast Cancer Cells 16%
• Overexpression 16%
• Cancer Cells 16%
• Clinical Response 16%
• Breast Cancer Patients 16%
• Antiproliferative Activity 16%
• Bcl-2 Family Proteins 16%
• Induced Apoptosis 16%
• Pharmacokinetics 16%
• Poor Prognosis 16%
• Anti-apoptotic Proteins 16%
• Tyrosine Kinase Inhibitor 16%
• ErbB1 16%
• Heavily Pretreated 16%
• ErbB2 16%
• Tyrosine Kinase 2 (TYK2) 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Epidermal Growth Factor Receptor 100%
• Lapatinib 66%
• Neoplasm 33%
• Protein Tyrosine Kinase 33%
• 2 Amino 6 Bromo 4 (1 Cyano 2 Ethoxy 2 Oxoethyl) 4h Chromene 3 Carboxylic Acid Ethyl Ester 33%
• Obatoclax 33%
• Malignant Neoplasm 16%
• Receptor 16%
• Tamoxifen 16%
• Clinical Trial 16%
• Advanced Cancer 16%
• Antiapoptotic 16%
• Protein Tyrosine Kinase Inhibitor 16%
• Tetrazolium 16%